Anticancer Drugs From Zeneca in Regulatory Phase of Development
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogen agent, has received approval for marketing in the United Kingdom for the treatment of advanced prostate cancer. Zeneca has also filed for approval of Casodex in the United States and several other countries, Zeneca president Robert C. Black said at a media briefing.
NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogenagent, has received approval for marketing in the United Kingdomfor the treatment of advanced prostate cancer. Zeneca has alsofiled for approval of Casodex in the United States and severalother countries, Zeneca president Robert C. Black said at a mediabriefing.
Other new anticancer agents from Zeneca in clinical developmentinclude Tomudex, a cytotoxic thymidylate synthase inhibitor forcolorectal cancer, and Arimidex, an oral nonsteroidal aromataseinhibitor for breast cancer.
The company's LHRH agonist analog Zoladex (goserelin acetate),currently marketed as a 3.6 mg implant for prostate cancer, hasbeen recommended for a new indication--palliation of advancedbreast cancer . An NDA has also been filed for a 10.8-mg, 3-monthdepo formulation, Mr. Black said.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
